New hope for painful hand and foot skin disease: experimental drug enters trial

NCT ID NCT07503652

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new biologic drug called Xeligekimab in 10 adults with moderate to severe palmoplantar pustulosis (PPP), a chronic skin disease causing painful blisters and scales on the palms and soles. The goal is to see if the drug can reduce symptoms and improve quality of life. Participants must have tried other treatments without success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS (PPP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • First Hospital of China Medical University

    RECRUITING

    Shenyang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.